We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation (AFib).
The double-blind, placebo-controlled first-in-human dose escalation study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3670549 in healthy participants.
AFib is a common heart rhythm disorder that affects around 60 million people across the world. AFib is a notable risk factor for stroke and heart failure.
Per management, the current standard for treating acute AFib episodes is electric cardioversion (ECV). However, the process remains challenging as it requires sedation or anesthesia to safely deliver an electrical shock to the patient’s heart in order to restore its normal sinus rhythm.
BAY 3670549 has the potential to help control the electrical activity of cardiomyocytes in patients with AFib.
The successful development of BAY 3670549, should strengthen Bayer’s cardiovascular portfolio.
BAYRY Stock Performance
Year to date, shares of Bayer have rallied 36.7% against the industry’s decline of 3.9%.
Image Source: Zacks Investment Research
BAYRY's Encouraging Pipeline Progress
Bayer is making good pipeline progress with some clinical milestones expected later in 2025. Bayer has also made some notable mergers and acquisitions to diversify and boost its portfolio of drug candidates.
The company plans to launch new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain form of heart disease. In February 2025, acoramidis was granted regulatory approval in the EU under the brand name Beyonttra.
Bayer had acquired marketing rights to the cardiovascular candidate acoramidis in Europe from BridgeBio (BBIO - Free Report) . The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.
Bayer has expanded its pipeline in new modalities to include competencies in cell therapy through the acquisition of BlueRock and in gene therapy through the acquisition of AskBio.
Bayer, together with its subsidiaries, BlueRock and AskBio, is developing preclinical and clinical cell and gene therapies for treating various disorders, including congestive heart failure and Parkinson's disease, among others.
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 11.8%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have increased 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Bayer AG (BAYRY - Free Report) announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation (AFib).
The double-blind, placebo-controlled first-in-human dose escalation study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3670549 in healthy participants.
AFib is a common heart rhythm disorder that affects around 60 million people across the world. AFib is a notable risk factor for stroke and heart failure.
Per management, the current standard for treating acute AFib episodes is electric cardioversion (ECV). However, the process remains challenging as it requires sedation or anesthesia to safely deliver an electrical shock to the patient’s heart in order to restore its normal sinus rhythm.
BAY 3670549 has the potential to help control the electrical activity of cardiomyocytes in patients with AFib.
The successful development of BAY 3670549, should strengthen Bayer’s cardiovascular portfolio.
BAYRY Stock Performance
Year to date, shares of Bayer have rallied 36.7% against the industry’s decline of 3.9%.
Image Source: Zacks Investment Research
BAYRY's Encouraging Pipeline Progress
Bayer is making good pipeline progress with some clinical milestones expected later in 2025. Bayer has also made some notable mergers and acquisitions to diversify and boost its portfolio of drug candidates.
The company plans to launch new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain form of heart disease. In February 2025, acoramidis was granted regulatory approval in the EU under the brand name Beyonttra.
Bayer had acquired marketing rights to the cardiovascular candidate acoramidis in Europe from BridgeBio (BBIO - Free Report) . The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.
Bayer has expanded its pipeline in new modalities to include competencies in cell therapy through the acquisition of BlueRock and in gene therapy through the acquisition of AskBio.
Bayer, together with its subsidiaries, BlueRock and AskBio, is developing preclinical and clinical cell and gene therapies for treating various disorders, including congestive heart failure and Parkinson's disease, among others.
BAYRY's Zacks Rank & Other Stocks to Consider
Bayer currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) and Amarin Corporation (AMRN - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 11.8%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have increased 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%.